CHINA PHARMA HOLDINGS, INC. — fact timeline

CHINA PHARMA HOLDINGS, INC. issued 12,600,000 restricted shares of common stock to Xiaoyan Zhang or designated third party for $6.93 million at $0.55 per share.

“research and development, writing of registration materials, registration application and other technical services. The transfer price as contemplated by the Agreement is $6.93 million, which will be paid in the form of common stock of the Company, par value $0.001 per share, at $0.55 per share. echnical services. The transfer price as contemplated by the”

CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Xiaoyan Zhang valued at $6.93 million (effective 2026-02-26).

“On February 26, 2026 (the “Signing Date”), Hainan Helpson Medical & Biotechnology Co., Ltd (“ Helpson ”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “ Company ”), entered into a Technology Transfer Agreement (the “ Agreement ”) with Xiaoyan Zhang (the “ Transferor ”). The Transferor owns an invention patent of an Prinsepia Utilis Esterol Sublingual Tablets and Method for Its Preparation (the “ Invention Patent ”). Pursuant to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide relevant technical services, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services. The transfer price as contemplated by the Agreement is $6.93 million, which will be paid in the form of common stock of the Company, par value $0.001 per share, at $0.55 per share.”

CHINA PHARMA HOLDINGS, INC. issued 12,600,000 restricted shares of common stock of common stock to Xiaoyun Chen for $8.82 million.

“research and development, writing of registration materials, registration application and other technical services. The transfer price as contemplated by the Agreement is $8.82 million, which will be paid in the form of common stock of the Company, par value $0.001 per share, at $0.70 per share. The closing is expected to be completed by February 20, 2026.”

CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Xiaoyun Chen valued at $8.82 million in common stock at $0.70 per share (effective 2026-02-05).

“On February 5, 2026 (the "Signing Date"), Hainan Helpson Medical & Biotechnology Co., Ltd (" Helpson "), a wholly owned subsidiary of China Pharma Holdings, Inc. (the " Company "), entered into a Technology Transfer Agreement (the " Agreement ") with Xiaoyun Chen (the " Transferor ").”

CHINA PHARMA HOLDINGS, INC. issued 7,000,000 restricted shares of Common Stock of common stock to Juan Zhang for $9.8 million, which will be paid in the form of common stock.

“research and development, writing of registration materials, registration application and other technical services. The transfer price as contemplated by the Agreement is $9.8 million, which will be paid in the form of common stock of the Company, par value $0.001 per share (the “ Common Stock ”), at $1.40 per share. transfer price as contemplated by the”

CHINA PHARMA HOLDINGS, INC. issued 3,500,000 restricted shares of Common Stock of common stock to Lijie Tang for $6.3 million, $1.80 per share.

“research and development, writing of registration materials, registration application and other technical services. The transfer price as contemplated by the Agreement is $6.3 million, which will be paid in the form of common stock of the Company, par value $0.001 per share (the “ Common Stock ”), at $1.80 per share. transfer price as contemplated by the”

CHINA PHARMA HOLDINGS, INC. engaged Enrome LLP as its auditor.

“udit committee approved the engagement of Enrome LLP (“ Enrome ”) as the Company’s new independent registered public accounting firm.”

CHINA PHARMA HOLDINGS, INC. dismissed B F Borgers CPA PC as its auditor.

“F Borgers CPA PC (“ Borgers” ), denying its privilege of appearing or practicing before the SEC as an accountant. As a result of the Order, Borgers may not participate in or perform the audit or review of financial information included in the SEC filings, issue audit reports included in the SEC filings, provide consents with respect to audit reports, or otherwise appear or practice before the SEC. On May 7, 2024, China Pharma Holdings, Inc. (the “ Company ”), a corporation incorporated under the laws of the State of Nevada, terminated the engagement with Borgers serving as the Company’s independent registered public accounting firm. The termination of the engagement with Borgers was approved by the Company’s audit committee.”

CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Lihua Li valued at $1.50 million (effective 2024-02-02).

“ntered into a Technology Transfer Agreement (the “ Agreement ”) with Lihua Li (the “ Transferor ”). The Transferor owns an invention patent of a pharmaceutical composition for treatment of psoriasis (the “ Invention Patent ”).”

CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Tao Liu valued at $1.65 million (effective 2023-12-15).

“On December 15, 2023, Hainan Helpson Medical & Biotechnology Co., Ltd (“ Helpson ”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “ Company ”), entered into a Technology Transfer Agreement (the “ Agreement ”) with Tao Liu (the “ Transferor ”).”

CHINA PHARMA HOLDINGS, INC. shareholders approved Amend the Articles of Incorporation to effect a reverse stock split at a ratio of up to 1:10 at the 2023-12-17 meeting.

“3. A proposal to amend the Company’s Articles of Incorporation to effect a reverse stock split at a ratio of up to 1:10, such that every holder of common stock, par value $0.001 per share, of the Company, shall receive one share of Common Stock for up to every ten shares of Common Stock held: Votes For Votes Against Abstentions 17,060,203 165,541 253 Pursuant to the foregoing votes, an amendment to the Company’s Articles of Incorporation to effect a reverse stock split at a ratio of up to 1:10, such that every holder of common stock, par value $0.001 per share, of the Company, shall receive one share of Common Stock for up to every ten shares of Common Stock held was approved and adopted.”

CHINA PHARMA HOLDINGS, INC. shareholders approved Adopt Amendment No.1 to the Amended and Restated 2010 Long-Term Incentive Plan at the 2023-12-17 meeting.

“2. A proposal to adopt the Amendment No.1 to the Company’s Amended and Restated 2010 Long-Term Incentive Plan: Votes For Votes Against Abstentions 17,073,265 147,382 5,350 Pursuant to the foregoing votes, the Amendment No.1 to the Company’s Amended and Restated 2010 Long-Term Incentive Plan was approved and adopted.”

CHINA PHARMA HOLDINGS, INC. shareholders approved Election of three independent director nominees to the Board of Directors at the 2023-12-17 meeting.

“1. A proposal to elect three independent director nominees to our Board of Directors: Independent Director’s Name Votes For Votes Withheld Gene Michael Bennett 17,174,742 51,255 Yingwen Zhang 17,165,245 60,752 Baowen Dong 17,165,232 60,765 Pursuant to the foregoing votes, Gene Michael Bennett, Yingwen Zhang and Baowen Dong were elected to serve as our independent directors until the next annual meeting and until their successors are elected and qualified.”

CHINA PHARMA HOLDINGS, INC. amended Amendment to Convertible Promissory Note with Streeterville Capital, LLC valued at Extended maturity date to May 19, 2024; extension fee of 2% of outstanding balance; reduced conversi (effective 2023-04-13).

“On April 13, 2023, China Pharma Holdings, Inc. (the “Company”) entered into an Amendment (the “Amendment”), to the Convertible Promissory Note (the “Note”) the Company issued to an institutional accredited investor Streeterville Capital, LLC (“Investor”) pursuant to a Securities Purchase Agreement (the “Agreement”) dated November 17, 2021. The Investor and the Company have agreed, according to the terms of the Amendment, to extend the maturity date of the Note to May 19, 2024. In consideration to the extension, the Company has agreed to pay to the Investor an extension fee equal to two percent (2%) of the outstanding balance of the Note, decrease the price at which the Investor can convert portions of the Note’s outstanding balance to the Company’s common stock, and assume an additional obligation to redeem a portion of the outstanding balance of the Note monthly or be subject to additional penalty fees. The Amendment also includes customary representations and warranties by the Compan”

CHINA PHARMA HOLDINGS, INC. shareholders approved Amendment to Articles of Incorporation to increase authorized shares from 95,000,000 to 500,000,000 at the 2022-12-27 meeting.

“4. A proposal to amend the Company’s Articles of Incorporation to increase the number of authorized shares of common stock from 95,000,000 shares to 500,000,000 shares, par value US$0.001 per share: Votes For Votes Against Abstentions 30,084,494 1,171,098 19,484 Pursuant to the foregoing votes, an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of common stock from 95,000,000 shares to 500,000,000 shares, par value US$0.001 per share was approved and adopted.”

CHINA PHARMA HOLDINGS, INC. shareholders approved Amendment to Articles of Incorporation to effect a reverse stock split at a ratio of up to 1:10 at the 2022-12-27 meeting.

“3. A proposal to amend the Company’s Articles of Incorporation to effect a reverse stock split at a ratio of up to 1:10, such that such that every holder of common stock, par value $0.001 per share, of the Company, shall receive one share of Common Stock for up to every ten shares of Common Stock held: Votes For Votes Against Abstentions 30,927,745 325,290 22,041 Pursuant to the foregoing votes, an amendment to the Company’s Articles of Incorporation to effect a reverse stock split at a ratio of up to 1:10, such that such that every holder of common stock, par value $0.001 per share, of the Company, shall receive one share of Common Stock for up to every ten shares of Common Stock held was approved and adopted.”

CHINA PHARMA HOLDINGS, INC. shareholders approved Adoption of Amended and Restated 2010 Long-Term Incentive Plan at the 2022-12-27 meeting.

“2. A proposal to adopt the Company’s Amended and Restated 2010 Long-Term Incentive Plan: Votes For Votes Against Abstentions 27,482,540 824,658 37,203 Pursuant to the foregoing votes, the Company’s Amended and Restated 2010 Long-Term Incentive Plan was approved and adopted.”

CHINA PHARMA HOLDINGS, INC. shareholders approved Election of three independent director nominees at the 2022-12-27 meeting.

“1. A proposal to elect three independent director nominees to our Board of Directors: Independent Director’s Name Votes For Votes Withheld Gene Michael Bennett 27,736,831 607,570 Yingwen Zhang 27,713,978 630,423 Baowen Dong 27,712,397 632,004 Pursuant to the foregoing votes, Gene Michael Bennett, Yingwen Zhang and Baowen Dong were elected to serve as our independent directors until the next annual meeting and until their successors are elected and qualified.”

CHINA PHARMA HOLDINGS, INC. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii)).

“if it has reported losses from continuing operations and/or net losses in its four most recent fiscal years. The Deficiency Letter noted that Company had stockholders’ equity of $2.8 million as of September 30, 2022, and has reported losses from continuing operations and/or net losses in its four most recent fiscal years ended December 31, 2021. The Company remains”

CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Contract with Chengdu Bonier Medical Technology Development Co., Ltd valued at RMB 15 million, approximately $2.1 million (effective 2022-11-28).

“On November 28, 2022, Hainan Helpson Medical & Biotechnology Co., Ltd (“Helpson”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “Company”), entered into a Technology Transfer Contract (the “Agreement”) with Chengdu Bonier Medical Technology Development Co., Ltd (“Bonier”).”